依维莫司是一种哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)抑制剂,可改善晚期激素受体阳性/人表皮生长因子受体2阴性(hormone receptor-positive/hu-man epidermal growth factor receptor 2-negative,HR+/HER2-)乳腺癌患者的预后.然而,依维莫司耐药日益发展,缺乏有效的标志物预测其疗效,对其临床应用造成了挑战.针对这一重要的临床问题,全文整理了近年来mTOR抑制剂的耐药机制及依维莫司疗效预测标志物的相关研究,以期提供参考.
Progress on Mechanism of Resistance to mTOR Inhibitor and Predicting Biomarkers for Everolimus Efficacy
Everolimus,a mammalian target of rapamycin(mTOR)inhibitor,has been shown to improve survival of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)advanced breast cancer.However,resistance to everolimus has been in-creasingly developed,and there is no efficient biomarker to predict its efficacy,which becomes a challenge for the clinical use of everolimus.This paper reviews the mechanisms of resistance to mTOR inhibitor and potential markers that can predict the efficacy of everolimus.
breast cancerdrug resistancemammalian target of rapamycin inhibitoreverolimuspredictive marker
万方数据
维普
